The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Carey K. Anders
No relevant relationships to disclose
Allison Mary Deal
No relevant relationships to disclose
Elizabeth Claire Dees
Research Funding - GlaxoSmithKline; Millennium; Novartis; Roche/Genentech
William Johnson Irvin
No relevant relationships to disclose
Hyman Bernard Muss
No relevant relationships to disclose
Jeanne Noe
Stock Ownership - Novartis
Olga Karginova
No relevant relationships to disclose
Barbara Adamo
No relevant relationships to disclose
Aleix Prat
No relevant relationships to disclose
Lisa A. Carey
No relevant relationships to disclose